Markets

Novavax Earns $125M Milestone Payment With Initiation Of Sanofi's Phase 3 Influence-COVID-19 Combination Vaccine Study Through Nuvaxovid

Oct 29, 2026 · 09:40 AM ET· updated 1h ago

Novavax (NASDAQ:NVAX) has earned a $125 million milestone payment with the initiation (fifth patient dosed) of Sanofi's Phase 3 influenza-COVID-19 combination vaccine trial utilizing Novavax's COVID-19 vaccine,

Why It Matters

Novavax got paid $125 million because a big partner started testing a new vaccine. This shows their vaccine technology is valuable and companies want to use it.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

NVAX10.48

+0.15 (+1.50%)

SNY42.33

+0.09 (+0.21%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.